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Objective: To determine whether similar mutations to quinolone resistance in the gyrA subunit of DNA gyrase and the 
parC subunit of topoisomerase IV are occurring independently in genotypically unrelated clinical isolates of 
Acinetobacter spp., or whether worldwide clonal spread of particular resistant strains is occurring. 
Methods: The genotypic relationships of 25 nosocomial isolates of Acinetobacterspp. from 15 locations in 11 different 
countries worldwide were examined by randomly amplified polymorphic DNA analysis. Quinolone resistance- 
determining regions of gyrA and parCwere amplified by PCR and mutations were analyzed by restriction digestion with 
Hinfl and DNA sequencing. 
Results: Twenty-four of the 25 Acinetobacter isolates were genotypically heterogeneous and 12 were resistant to both 
nalidixic acid and ciprofloxacin. Analysis of conserved gyrA and parC regions showed that all isolates with a 
ciprofloxacin MIC of 4 mg/L had a substitution of Ser83 with either Leu or Phe in  the GyrA protein. Five of six isolates 
with ciprofloxacin MlCs of 64 mg/L had additional substitutions of Ser8O with Leu in the ParC protein. 
Conclusions: Similar mutations to quinolone resistance, predominantly at codons 82-83 of gyrA, are occurring 
independently in genotypically distinct isolates of Acinetobacterspp. from different worldwide locations. Most isolates 
with high ciprofloxacin MlCs also exhibited secondary mutations in parC at codons 79-80. 
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INTRODUCTION 
Opportunistic infections caused by Acirietobarrer spp., 
predominantly A.  Dairri~arrriii, include bacterernia, urin- 
ary tract infections and meningitis [ 1 ]. These organisms 
also play a significant role in intensive care units, 
where they are associated predominantly with noso- 
coinial pneunionia [2-41. Such infections are often 
difficult to treat because of the organism’s ability to 
become resistant rapidly to multiple groups of anti- 
biotics, including the aniinoglycosides and third- 
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generation cephalosporins. Until 1988, the fluoro- 
quinolones had excellent activity against Acirietobnrtcr 
spp., but widespread use ha? resulted in the eniergence 
of resistance [5,6]. This resimnce has been attributed 
to chromosomal mutations that alter either DNA g r a s e  
or topoisomerase IV, the cellular targets of the fluoro- 
quinolones, or to mutations that reduce the intracellular 
drug concentration by one of several mechanisms [7] .  
DNA =rase (topoisomerase 11) is the primary 
target of the fluoroquiriolones in Gram-negative 
bacteria and is essential for LINA synthesis. Structural 
alterations in this enzyme have been shown in a wide 
range of bacterial species to be associated with a 
decrease in susceptibility to the fluoroquinolones 181. 
T h e  enzyme is composed of two A subunits and two 
U subunits, encoded by the g)’rA and XyrB genes, 
respectively. Specific mutations have been found in 
quinolone-resistant EicIier;cliia moli, resulting in substitu- 
tions of amino acids SerX3 and Asp87 in the A subunit 
[ 91. Mutations in2))rB appear to contribute to decreased 
susceptibility, but are rare [ 10,l  1 1.  
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Topoisomerase IV, with a structure similar to DNA 
gyrase, is a secondary target for the fluoroquinolones in 
E. coli [12]. The two subunits of this enzyme are 
encoded by parC and parE. It has been shown in E.  coli 
that mutations in the region of parC equivalent to 
the quinolone resistance-determining region (QRDR) 
of gyrA are also involved in the acquisition of fluoro- 
quinolone resistance [13,14]. Mutations in parE are not 
found commonly in ciprofloxacin-resistant isolates of 
E .  coli [9] .  Other mechanisms reported to be involved 
in quinolone resistance include changes in the cell 
envelope as a result of loss of outer-membrane porins 
and alterations in lipopolysaccharide that are associated 
with intracellular accumulation of antibiotic [ 151. 
Expression of the inducible multiple antibiotic resistance 
(mar) locus confers resistance to multiple drug types via 
an active efflux system and may also play a role in 
quinolone resistance [ 16,171. 
So far as Acinetobacter spp. are concerned, mutations 
resulting in amino acid substitutions in GyrA and ParC, 
most commonly at Ser83 and Ser80, respectively, have 
been associated with fluoroquinolone resistance in 15 
resistant isolates of A. baumannii collected from three 
hospitals in Spain [18,19]. The aim of the present 
study was to investigate whether similar independent 
mutations in XyrA  and parC are resulting in quinolone 
resistance emerging in worldwide, genotypically un- 
related clinical isolates of Acinetobacter spp., or whether 
clonal spread of particular quinolone-resistant isolates 
has occurred in response to increasing selection pres- 
sures. 
MATERIALS AND METHODS 
Bacteria and susceptibility testing 
In total, 25 nosocomial Acinetobarter isolates from 
15 different locations in 11 countries were studied 
(Table 1). All had been identified previously to the 
genomic species level by the tDNA profile method 
[20]. Minimal inhibitory concentrations (MICs) were 
determined by an agar dilution method in which -lo4 
colony-forming units (CFU) were inoculated onto 
Isosensitest Agar (Oxoid, UK) containing doubling 
dilutions of nalidixic acid (Sigma, Poole, Dorset, UK) 
or ciprofloxacin (Bayer, Newbury, Berkshire, UK). The 
MIC was taken as the lowest concentration of drug 
required to totally inhibit growth after incubation at  
30°C for 18 h. The isolates were stored at -70°C in 
Skim Milk Powder (Oxoid, Basingstoke, Hampshire, 
UK) 10% w/v in sterile distilled water and then 
subcultured onto Cysteine Lactose Electrolyte Deficient 
Agar (Oxoid, UK) and incubated overnight at  30°C 
before further molecular analysis. 
Determination of genotypic relationships by DNA 
fingerprinting 
The genotypic relationships between the isolates were 
investigated by analysis with DENDRON v. 2.3 
(Solltech, Oakdale, IA, USA) of randomly amplified 
polymorphic DNA (RAPD) fingerprints, obtained 
following amplification with either M13 core region or 
DAF4 primers, as described in detail previously [21]. 
The DENDRON program identifies the positions and 
intensities of the components of a DNA fingerprint and 
then calculates a similarity coefficient (Sm) for each 
individual pair of strains. The SAB values are presented 
in a matrix and then used to generate a dendrogram 
showing the genotypic relationships of the collection of 
strains studied [21]. 
Release of genomic DNA and amplification of the 
QRDR of gyrA and parC by polymerase chain reaction 
(PCR) 
Total genomic DNA was released from bacteria by 
resuspending a loopful of culture in 50 pL of sterile 
water and heating at 95 “C for 15 min. The crude DNA 
suspension was cooled on ice, diluted 1:10 with sterile 
distilled water, centrifuged for 1 min and stored at 
-20°C until required. 
PCRs for the QRDRs  ofgyrA and parC, respec- 
tively, were performed with the following primer sets 
[18,19]: GYR1, 5’-AAATCTGCCCGTGTCGTT- 
GGT-3’ and GYR2, 5’-GCCATAACCTACGGCG- 
ATACC-3’; and PAR1 , 5’-AAACCTTGTTCAG- 
CGCATT-3’ and PAR2, 5‘-GTGGTGGCCGTTA- 
AGCAAA-3’. All primers were custom-synthesized by 
Oswel DNA Service (Southampton, UK). Individual 
reaction mixtures (25 pL) for gyrA and parC contained 
1 x buffer, 200 pM deoxynucleoside triphospbates, 
3.0 mM magnesium chloride, 0.6 U Taq polymerase 
(Promega, Southampton, UK), 2.5 pmol of each 
primer and 5 pL DNA extract. Amplification profiles 
were as described previously [ 18,191. Amplified DNA 
products were separated on agarose 1.5% W/V gels, 
stained with ethidium bromide and visualized on a UV- 
transilluminator. 
Digestion of the PCR product with Hinfl 
Previous studies of the conserved QRDRs of gyrA and 
parC of A. baunzannii have identified the presence of 
H i n f f  restriction sites (GANTC) at the codons for 
amino acids Asp-Ser 82-83 and 79-80, respectively 
[18,19]. Portions (25 pL) of the P C R  products were 
incubated at 37°C for 1 h with 10 U of Hinfl 
(Boehringer Mannheim, Lewes, East Sussex, UK) in 
the buffer recommended by the manufacturer. The 
digestion products were separated by electrophoresis in 
agarose 1.5% w/v gels and visualized as above. DNA 
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Table 1 Source and susce~tibilitv to quinolones of Ariwtobatrr isolates studied 
MIC (mg/L) 
Iiolatc Origin Identification‘ Nalidixic acid Ciproflosaciii 
cw 1 
CW5 
cw11 
CW12 
cw13 
CW14 
CWZO 
CW22 
CW27 
CW28 
CW31 
CW32 
(;1 
(;5 
S2 
S4 
Al 
A10 
13 1 
I3 i 
111 
112 
ESP41 
ESP77 
113.3 
Nottingham, U K  
Nottinghani, UK 
13risto1, U K  
13ri\toI. UK 
Kotterdam, The Netherlmck 
Venlo, The Netherlands 
Paris. France 
I’aris, France 
Cardit?-, UK 
East Glainorgan, U K  
Pcr-th. Australia 
Perth, Australia 
Chpr Town. South Afric‘i 
Capc Town. South Africa 
Singap or? 
Singapore 
Buenoi Airei, Argentina 
13uciios Aircs. Argcntinci 
Berlin, Gcrmany 
I3erlin, (;el inany 
Freiburg, Gcriiiany 
Frciburg, Gcrmany 
~ ~ ~ l r c e ~ o n a ,  Spain 
Barccloiid, Spdiii 
Tricste, Italy 
A .  bnrr~~tarrrrii 
A bar r i~ rnr~r i i i  
Ari~rctoburrcr sp. 3 
Acriietobartcr sp. 3 
A ~ i n 1 4 ~ ~ 1 m r 1 i i  
A. bannrar~iiri 
A. iiaurtraiiiiii 
A. bnirinaririii 
A. ~>aulii~llllii  
A .  hniinraririii 
Aririrtnbartrv ip. 3 
A bniirrrarrirri 
‘4. bnumarrrirr 
‘4 b,iiirnariiiri 
A bnrrnrarrriii 
A. barimaririii 
A. bn~rn~arrriri 
A harrrrinririri 
il barimarrrrir 
.4 bnrtrnnrrriii 
.4. bniiir~arrrrii 
‘4. lar~niuri i i i r  
A barrirtniririi 
.4 bniinimriii 
A bauirtari~i ir  
X 
32 
8 
4 
> 1024 
> 1025 
> l(l2.1 
256 
> 1024 
> 1024 
X 
4 
4 
4 
> 1024 
> 1024 
8 
> 1024 
32 
32 
8 
> 1024 
> 1024 
32 
5 
0.5 
( 1  -5 
0.5 
11.5 
I (1 
6 1 
61 
4 
32 
32 
1 
11.5 
11.5 
(1.5 
64 
(1 5 
il.5 
11.5 
lJ..5 
(1.5 
(1 4 
61 
1 h 
0,s 
11.5 
’ Identified by tI1NA tingerprinting iiiethod [XI] 
size marker?, run on the same gel, comprised a 100-bp 
DNA ladder (Promega, USA). 
Sequencing of PCR products 
Primers and free nucleotides were removed from I’CR 
products by incubating with 10 U exonuclease I and 
3 U shrimp alkaline phosphatase (Cambridge Bio- 
science, Cambridge, UK) at 37 “C for 15 min, followed 
by heat inactivation at 70°C for 10 min. The purified 
product was then processed for DNA sequencing with 
an ABI PRISM Dye Terminator Cycle Sequencing 
Ready Reaction Kit incorporating AmpliTaq DNA 
polymerase, FS (Perkin Elmer, Warrington, UK), used 
according to the manufacturer’s instructions, followed 
by analysis in an ABI Prism 31 0 Gene Analyser (Perkin 
Elmer). Cycle sequencing was performed with either 
GYKl or PAK1, as appropriate. 
RESULTS 
Table 1 shows the identification, source and quinolone 
susceptibility of the 25 Acinetobactev isolates included in 
the study. The isolates varied in their Fensitivity to the 
quinolone7, with MICs of nalidixic acid and cipro- 
floxacin between 4 and > 1024 mg/L and 0.5 and 
64 ing/L, respectively. 
RAPL) fingerprint profiles, obtained following 
amplification with the M13 core primer, for the 11 
isolates with a nalidixic acid MIC of >64 mg/L con-  
prised up to I6  amplification products. The dendro- 
gram derived from these profiles following analysis 
by the DENDRON program is shown in Figure 1. 
Although the two isolates from Wales (isolates CW27 
and CW2X) appeared to be identical, the reinainder of 
these isolates with high levels of quinolone resistance 
were shown to be genotypically heterogeneous. This 
was confirmed by the similar results obtained following 
analysis of KAPD fingerprints generated with the 
DAF4 primer (results not shown). 
Amplification by PCR of the conserved Q R D K  
of the gyvA gene yielded a PCR product of343 bp from 
each isolate, as predicted by a previous study confined 
to isolates from three hospitals in Spain 1181. Hinfl 
digestion of the PCR products from the isolates with 
nalidixic acid MICs of 6 3 2  mg/L and ciprofloxacin 
MICs of 0.5 nig/L produced two fi-agrnents of 201 bp 
and 52 bp, except for one isolate (CW31) with a 
nalidixic acid MIC of 8 ing/L that failed to cut. 
Lligestion of the PCK products from the 11 isolates 
with a nalidixic acid MIC of >64 mg/L also failed 
to yield two fragments, indicating abolition of the 
restriction site at the codons for amino acids 82-83. 
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Figure 1 Dendrogram, based on RAPD fingerprints obtained with the M13 core primer, illustrating the similarity 
coefficients (Sm values) for the 11 isolates of Acinetobacter spp, with a nalidixic acid MIC of >64 mg/L. 
Sequencing ofthe PCR products obtained fi-om CW31 
And the 11 isolates with a high nalidixic acid MIC 
revealed a change from Ser to Leu at amino acid 83 in 
11 of the 12 isolates. Isolate CW27 had a change at 
Ser83 to Phe. The 13 other isolates with no change 
at Ser83 had codon TCA for this amino acid. The 
resistant isolates with the Ser83 to Leu substitution 
had a transversion of C+T in codon TCA, and CW27 
had a transversion of A+C in this codon. S2 had an 
additional substitution at amino acid 77 from Tyr to 
Cys. These results are summarized in Figure 2A. 
Amplification by P C R  with primers for the 
conserved Q R D R  of pavC also gave the predicted 
product of 327 bp [19]. Products of 206 bp and 121 bp 
were visualized after Hinfl digestion of the ampli- 
fication products from those isolates with ciprofloxacin 
MICs of 6 3 2  mg/L. The PCR product from isolate 
S4 (ciprofloxacin MIC of 64 mg/L) also yielded two 
fragments following Hinfl digestion. The remaining 
isolates (ciprofloxacin MICs of 64 rng/L) had mutations 
at  the codons for amino acids 79-80, since Hinfl 
digestion of the PCR products from these isolates was 
unsuccessfi~l. Sequencing showed that these high-level 
ciprofloxacin-resistant isolates had a substitution at 
Ser80 with Leu. All contained a transversion of C-+T 
in the corresponding codon (Figure 2B). No other 
mutations were found. No parC mutation occurred 
without a concomitant mutation in gyr.4. 
DISCUSSION 
Previous studies in 15 clinical isolates of A. baumannii 
from three hospitals in Spain have associated mutations 
in gyti4 and parC with fluoroquinolone resistance 
118,191. The aim of this study was to determine 
whether similar mutations were occurring independ- 
ently in isolates or whether resistant phenotypes are 
spreading clonally. Of  the 25 isolates of Aci~etabacter spp. 
studied, cluster analysis results following DNA finger- 
printing showed that 10 of the highly resistant isolates 
were genotypically heterogeneous. Nevertheless, all 10 
had a substitution from Ser to Leu at codon 83 of GyrA, 
and the final isolate (CW27, genotypically identical to 
CW28) had a different substitution from Ser to Phe at 
codon 83. This mutation found in CW27 has not been 
reported previously in Acinetobacter spp., but is common 
in other quinolone-resistant Gram-negative bacteria 
[22,23]. A second mutation was found in the gyrA gene 
of isolxe S2 at codon 77. One of the relatively sensitive 
isolates (CW31), belonging to Acinetobacter sp. 3, also 
had a substitution in GyrA of SerX3 with Leu, but had 
nalidixic acid and ciprofloxacin MICs of only 8 mg/L 
and 1 mg/L, respectively. 
Of  the 11 isolates with resistance to ciprofloxacin 
(MIC 4 mg/L), five had additional mutations at 
codon 80 in parC leading to substitution of Ser with 
Leu. These isolates all exhibited high-level resistance 
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Figure 2 Partial DNA sequences showing the conserved QKDKs of (A) the gyrA and (B) the p n r C  genes of quinolone- 
susceptible and -resistant isolates of A .  haumannii. The locations of the H i d  restriction sites are marked with arrows. The 
deduced amino acid sequence is given below the DNA sequence for a susceptible isolate (CW1). Other susceptible isolates 
also shared the consensus seauence. Deviations from the consensu? sequence are shown for the resistant isolates. 
~ ~~ 
(Ai 
MIC5 ( nig/L) 75 76 77 78 79 xo 81 82 83 84 85 86 87 88 89 90 
i (Nalidisic acid Ciprofloxa~in 
cw1* CGT AAA TAT CAC CCG CAT GGT GAC TCA GCT GTT TAT GAA ACC ATT GTT 8 1(1 J 
(Scncitive strain) Glv Lys Tyr Hir Pro Hir Gly Asp Ser Ala Val Tyr Glu Thr Ile Val 
cw13 . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T T A  . . . . . . . . . . . . . . . . . . . . . . . .  
Leu 
( X 4  . . . . . . . . . . . . . . . . . . . . . . . . . .  . . T T A  . . . . . . . . . . . . . . . . . . . . . . . . . .  
Lru 
c:w20 . . . . . . . . . . . . . . . . . . . . . . . . .  T T A  . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Lcu 
CW22 . . . . . . . . . . . . . . . . . . . . . . . . . .  TTA . . . . . . . . . . . . . . . . . . . . . . . . . .  
Leu 
c w 2 7  . . . . . . . . . . . . . . . . . . . . . . .  . . T K  . . . . . . . . . . . . . . . . . . . . . . . . . .  
Phe 
CW28 . . . . . . . . . . . . . . . . . . . . . . . . .  TTA . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Leu 
S2  . . . . .  . T G T  TTA 
c y \  Leu 
S4 . . . . . . . . . . . . . . . . . . . . . . . . . . .  T T A  . . . . . . . . . . . . . . . . . . . . . . . . .  
L r u  
A10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T T A  . . . . . . . . . . . . . . . . . . . . . . . . . .  
Let1 
1 j 2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  T T A  . . . . . . . . . . . . . . . . . . .  
Leu 
ESP41 . . . . . . . . . . . . . . . . . . . . . .  TTA . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Lru 
M ) 
72 73 74 75 76 77 78 70 81) 81 82 83 84 X i  86 87 
1 
(:wI* GGT AAA TAT CAC CCa C.4T GGT GAC TCG GCA TGT TAT GAA GC(: ATG GTA 
(Semitive strdin) Gly Lys Tyr Hi\ Pro His Gly A ~ I  Srr Ala Val CyS Glu  Ala Met Val 
<:w13 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
MICs ( ina/L) 
(Nalidis~c acid (:ipi-ofloxacin 
X 50.5 
> 1!124 16 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . .  (:wI4 TT(; > 1 u24 64 
CW21) T T G  >1!124 6 4 
cw22 2.5 6 4 
c w 2 7  >lo24 32 
CW28 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  > 11’124 S2  
Lcu 
LCU 
. . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
32 . . .  
S4 . . .  
TTG 
Leu 
. . .  21024 0 4 
. .  >lll24 (14 
. . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . .  A10 . . T T G  >1!124 6 4 
112 TTG >1024 0 4 
ESP4 I 111124 16 
Leu 
Leu 
. . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . .  
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
to ciprofloxacin, with MICs of > 64 mg/L. N o  purC 
mutation was found without a mutation in gyrA. Isolate 
S4 had a ciprofloxacin MIC of 64 mg/L, but no 
concomitant mutation in prC was found. A mutation 
in  another region of the purC gene that was not 
amplified may have been responsible for the increase in 
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resistance. Although such mutations are uncommon 
in E. coli, this isolate may have had further mutations 
in gyrB or parE which lead to an increase in MIC. 
Alternatively, drug-permeability and -efflux mechanisms 
may have been involved. However, a separate study has 
shown that diminished quinolone accumulation is 
unlikely to account for the high-level resistance of the 
A. baumannii isolates studied [24]. 
Overall, this work confirmed earlier findings that 
a change in Ser83 of GyrA is the predominant mutation 
responsible for quinolone resistance in A .  baurnarmii 
and generally confers ciprofloxacin MICs of 3 4 mg/L 
[18]. However, this mutation was also found in an 
isolate of Acinetobacter genospecies 3 which had a 
ciprofloxacin MIC of 1 mg/L. A double mutation in 
gyrA and parC has also been shown previously to be 
required for high-level resistance to ciprofloxacin 
(MICs of 64 mg/L) [19]. This was also found to be the 
case in this study. However, in contrast, the present 
study found that the gyrA mutation alone is sufficient 
to confer resistance to nalidixic acid at a concentration 
of >I024 mg/L. As described above, minor variations 
in resistance between isolates may reflect differences in 
drug-permeability and -efflux mechanisms. However, 
this study has shown that substitutions at Ser83 of GyrA 
and at Ser80 of Pare appear to be primarily responsible 
for quinolone resistance in the isolates of Acinetobacter 
spp. studied, and that these mutations are occurring 
independently in genotypically distinct worldwide 
isolates. Similar findings have been reported for E. coli 
and Klebsieh ynetrmoniae [25]. Further work is required 
to assess the contributions that mutations in other 
subunits of the proteins and other general resistance 
mechanisms make to quinolone resistance in occasional 
unusual isolates and also to study the relative effects that 
the mutations have among different genospecies of 
Acinetobacter. 
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